.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XA04_Satraplatin.Satraplatin .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XA04_Satraplatin.Satraplatin| name: | Satraplatin |
| ATC code: | L01XA04 | route: | oral |
| n-compartments | 2 |
Satraplatin is an oral platinum-based chemotherapeutic agent that was investigated for the treatment of advanced cancers, particularly prostate cancer. Unlike other platinum drugs such as cisplatin, satraplatin is orally bioavailable. Despite promising early-phase studies, satraplatin is not an approved drug today.
Pharmacokinetic parameters reported in adult cancer patients (typical age range 37-78 years) receiving oral satraplatin as monotherapy.
Sova, P, et al., & Chládek, J (2011). A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV). Cancer chemotherapy and pharmacology 67(6) 1247–1256. DOI:10.1007/s00280-010-1411-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20697713
Doshi, G, et al., & Sternberg, CN (2012). Clinical and pharmacokinetic evaluation of satraplatin. Expert opinion on drug metabolism & toxicology 8(1) 103–111. DOI:10.1517/17425255.2012.636352 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22098065
Galsky, MD, et al., & Bajorin, DF (2011). Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. Clinical genitourinary cancer 9(1) 27–30. DOI:10.1016/j.clgc.2011.05.003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21700509